Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1

ABSTRACT: Patient-derived AML191 (acute myeloid leukemia with inv3(q21;q26.2)), -7) cells were treated in duplicate with 100 nM of FHD-286 for 0, 8, 16, 24 and 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a small molecule, chromatin remodeling complex protein, dual SMARCA2/SMARCA4 enzymatic activity inhibitor in MECOM-rearranged AML cells with EVI1 overexpression.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain  

LAB HEAD: Kapil N. Bhalla

PROVIDER: PXD059059 | Pride | 2026-01-23

REPOSITORIES: Pride